Revolution Medicines Inc RVMD

$189.76 +1.64 (0.87%)

Valuation

Market cap
40,320,884,000
Revenue TTM
$0
Net income TTM
$-1,131,300,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.40

Trading

Volume
2,210,400
Avg volume
1,948,482
Day's range
$184.37 – $193.50
Shares out
214,336,000
Stochastic %K
31%
Beta
1.40
Analysts
Strong Sell
Price target
$253.04

Price

Company profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to s...

Show more

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 481 6801
Website
https://www.revmed.com
Address
700 Saginaw Drive, Redwood City, United States

Latest news

Stocktwits

Alt_Fuel Oct 10, 9:27 PM
$VSTM ​$RVMD @MindreaderBio $VSTM increasing awareness that VS 7375 might have a place in pancreatic cancer.Highly potent against KRAS G12D a subtype with $RVMD limitations. No effect on wild type KRAS so no dermatitis.October 14 8am Investor presentation. 8:55 PM · Oct 9, 2026 · 293 Views https://x.com/MindreaderBio/status/2108723052888346789
0 replies
BioTechHealthX Oct 10, 5:53 AM
$RVMD Revolution Medicines, Inc. (NASDAQ: RVMD) has FDA approval for RASONQUE. Explore its pancreatic cancer opportunity and the prescribing tests investors should watch. https://biotechhealthx.com/biotech-news/revolution-medicinesrvmd-has-an-approved-cancer-drug-but-can-sales-follow/
0 replies
WillieMays Oct 9, 9:02 PM
$IMRX Good luck to $RVMD $VSTM and other RAS inhibitors - especially with some recent concerns on $RVMD’s efficacy - but hopefully these inhibitors help PDAC patients. This is all occurring at the top of the MAPK pathway. The great news is - $IMRX’s Atebi is an MEK inhibitor working downstream on the MAPK pathway. Should $IMRX’s current Phase 3 trial (n=510) - replicate its amazing Phase 2 data on 55 patients (mOS 17.3mos - excellent tolerability) - then patients will potentially have a multitude of options. However the RAS protocol plays out - downstream Atebi would be a viable option - either - on its own (combo with chemo) - or together with the upstream RAS inhibitor. The risk/reward of $IMRX is incredible Market Caps $IMRX 250M $RVMD 41B I am not a scientist or a doctor - would love for someone to support or counter above thought process
1 replies
Alt_Fuel Oct 9, 7:42 PM
$RVMD The good Dr Tim provided valuable issues to consider... @DrTim $VSTM To me, yesterday's RVMD/FDA news was huge! Because I have been sitting here, hoping that we would at least get in the ballpark of RVMD's ORR for pancreatic cancer(and of course show superior tolerability). Now we learned that in the most common KRAS mutation in pancreatic cancer, RVMD's response rate is only 24% . I think that VSTM will greatly exceed this lowered threshold! I think we're sitting on the new standard of care for this KRAS mutation.  2:50 PM October 9, 2026
1 replies
55X_ROI_Q1_2026 Oct 9, 7:28 PM
$SLS 6 Fold Better than a $40B Platform Drug ... S $RVMD SLS009 is "6 Fold Better than Daraxonrasib." "The FDA has asked SLS009 tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia." Investment Opportunity of a Lifetime ahead of the GPS Phase 3 AML • Remission Results and SLS009 Pivotol AML-MR Results THIS QUARTER. Each Trial Result will likely add $25B + + the manipulated market value. $MRNA Moderna has now added $60B to its market cap since its Phase 3 Cancer Vaccine Results were announced. Sellas Life Sciences Phase 3 Cancer Vaccine Results for AML Remission Maintenance are now Imminent. $2.3B baby bio about to be $25B and climbing - it will happen any day now. I’ve been here a while scroll my posts for DD.
1 replies
Alt_Fuel Oct 9, 7:10 PM
$VSTM $RVMD FDA’s Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data By Angus Liu Oct 9, 2026 11:25am https://www.fiercepharma.com/pharma/fda-rasonque-review-documents-pressure-revmed-investors-jitter-over-kras-subgroup-data
0 replies
SellasgpsCurativeBAT11 Oct 9, 7:10 PM
$SLS $RVMD Penny Flippers good luck trying to catch $SLS under $15.00 come Tuesday. Breakthrough News will hit in waves now ! ✌️🙏❤️‍🩹
0 replies
55X_ROI_Q1_2026 Oct 9, 7:10 PM
$SLS $RVMD "6 Fold Better than Daraxonrasib." "The FDA has asked SLS009 tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia." Investment Opportunity of a Lifetime ahead of the GPS Phase 3 AML Remission Results and SLS009 Pivotol AML-MR Results THIS QUARTER. Each Trial Result will likely add $25B + + the manipulated market value. $MRNA Moderna has now added $60B to its market cap since its Phase 3 Cancer Vaccine Results were announced. Sellas Life Sciences Phase 3 Cancer Vaccine Results for AML Remission Maintenance are now Imminent. $2.3B baby bio about to be $25B and climbing - it will happen any day now. I’ve been here a while scroll my posts for DD.
0 replies